Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of Zoom meetings, Skype calls, and deadlines has predictably returned. But what can you do? The world, such as it is, keeps spinning. So we will give it a nudge with a delicious cup of stimulation. Our choice today is original glazed doughnut. Yum. Please feel free to join us. Meanwhile, here are some tidbits to get you going. We hope your day is successful, and do stay safe — wear a mask. …

AstraZeneca (AZN) reported that its Covid-19 vaccine was safe and 79% effective in preventing symptomatic disease in U.S. clinical trials involving more than 32,000 people, STAT writes. The move paves the way for likely authorization in the U.S. The studies showed the vaccine reduced severe Covid-19 and hospitalization by 100%, and that the vaccine was equally effective in people over 65, where it had 80% efficacy. The company also maintained it did not identify any new safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • An, “another sequel” … at least in title? The original was “Bad Blood” re Theranos – followed a year later by “Bad Bottle” on the offshore generic industry … now we have “Bad Medicine” about Purdue, although in this third volume the medicine actually worked … too well? I suspect I shall have to invest in yet another book, although this time via Kiindle.

Comments are closed.